RYAN MACKINNON VASAPOLI AND BERZOK, LLP for GENENTECH
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Comparative Effectiveness and H.R. 1 American Recovery and Reinvestment Act of 2009.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | LA Rep. Anna Eshoo (D-California) |
| JEFF MACKINNON | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Budget/Appropriations BUD
Comparative Effectiveness and H.R. 1 American Recovery and Reinvestment Act of 2009.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | LA Rep. Anna Eshoo (D-California) |
| JEFF MACKINNON | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Health Issues HCR
Monitor federal related to Medicare and other health care issues. Budget resolution FY2010, Pathway for Biosimilars Act (H.R. 1548). Health Care Reform Legislation. Pharmaceutical import safety legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | LA Rep. Anna Eshoo (D-California) |
| JEFF MACKINNON | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Medicare/Medicaid MMM
Comparative Effectiveness and H.R. 1 American Recovery and Reinvestment Act of 2009. Monitor federal related to Medicare and other health care issues. In addition, Patent Reform Act of 2009 (H.R. 1260/ S.515/ S. 610). Budget resolution FY2010, Pathway for Biosimilars Act (H.R. 1548). Health Care Reform Legislation. Pharmaceutical import safety legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | LA Rep. Anna Eshoo (D-California) |
| JEFF MACKINNON | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Pharmacy PHA
Issues regarding follow on biologics, HR 5629 Pathway for Biosimilar Act; S 1695 Biologics, Price Competition and Innovation Act of 2007, HR 1956 - provide for approval of similar biological products, HR 5629 - establish a pathway for the licensure of biosimilar biological products, HR 1038 - provide for licensing of comparable and interchangeable biological products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | LA Rep. Anna Eshoo (D-California) |
| JEFF MACKINNON | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ROCHE HOLDINGS LTD | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.